GlassScriptPhysician profile
Charles Eric Schroeder
NPI 1841265667
$1,517.62
in general payments reported to CMS, 2019-2025
22 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $286 · 2021: $138 · 2022: $293 · 2023: $410 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $199.60 | 2020-2025 | Tezspire, Breztri, Fasenra |
| Grifols USA, LLC | $185.88 | 2020-2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.23 | 2019-2022 | |
| Pulmonx Corporation | $160.71 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Glaxosmithkline, LLC. | $154.37 | 2019-2023 | Nucala |
| Mylan Specialty L.P. | $101.51 | 2020-2023 | Yupelri |
| Jazz Pharmaceuticals INC. | $84.19 | 2020-2023 | Xywav |
| Novocure INC. | $80.45 | 2020 | |
| Insmed, INC. | $51.06 | 2021-2023 | Arikayce |
| Therapeuticsmd, INC. | $40.71 | 2019-2020 | |
| Amgen INC. | $36.91 | 2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $35.72 | 2020 | |
| Apria Healthcare LLC | $32.17 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $31.83 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $27.82 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $25.18 | 2023 | Sunosi |
| Abbvie INC. | $19.60 | 2023 | Teflaro |
| Genzyme Corporation | $17.86 | 2025 | |
| United Therapeutics Corporation | $17.29 | 2019 | |
| Lundbeck LLC | $15.51 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.23 | 2019 | |
| Genentech USA, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.